Rosuvastatin Calcium

瑞舒伐他汀钙

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NameRosuvastatin Calcium
Drug Alias Name罗苏伐他汀钙RosuvastatineRosuvastatina罗舒伐他汀钙罗苏伐他汀 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaDepression +[57] 
Global Approved IndicationsHypercholesterolemiaDyslipidemiasHyperlipoproteinemia Type II
Approved Indications in ChinaHypercholesterolemiaHyperlipoproteinemia Type II
Original Approved Country/TerritoryNetherlands
Original Approved Date2002/11/06
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdCanadian Institutes Of Health Research (Cihr)Wake Forest University Health Sciences +[15] 
Inactive CompaniesDana-Farber Cancer InstituteAutonomous University Of San Luis PotosiRadboud University Medical Center +[31] 
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaFibrosis +[23] 
Inactive IndicationsDepressionBurnsIschemia +[34] 

Other Information

ATC CodeC10AA07
Related LinksWikipediaDrugBankKEGG